{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T07:29:58.532864+00:00","company":{"ticker":"WGS","cik":1818331,"company_name":"GeneDx Holdings Corp."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"c2ffd4b3d7af7f82c8d91ca31bb551cd6b761886","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$63.3 million","period_text":"first quarter of 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$102.3 million"},"claim":"GeneDx Holdings Corp. reported first quarter of 2026 results: revenue $102.3 million, net income $63.3 million.","evidence_excerpt":"reported first quarter 2026 revenue of $102.3 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818331-26-000039","anchor_url":"https://secwatch.observer/filing/0001818331-26-000039#claim-c2ffd4b3d7af7f82c8d91ca31bb551cd6b761886","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833126000039/0001818331-26-000039-index.htm"},{"fact_type":"debt_financing","fact_key":"21d346d3598761e082b5e2091106b86dbde17ee1","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"counterparty":"Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative”)","effective_date":"2026-02-27","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"Term SOFR adjusted secured overnight financing rate plus a margin of 4.50%","item_codes_triggered":["2.03"],"maturity_text":"five years from the Closing Date","principal_text":"$100.0 million"},"claim":"GeneDx Holdings Corp. incurred term loan of $100.0 million with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative”) at Term SOFR adjusted secured overnight financing rate plus a margin of 4.50% maturing five years from the Closing Date.","evidence_excerpt":"The Loan Agreement provides for a term loan in an aggregate principal amount of $100.0 million funded to the Company on the Closing Date (the “Term Loan”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818331-26-000021","anchor_url":"https://secwatch.observer/filing/0001818331-26-000021#claim-21d346d3598761e082b5e2091106b86dbde17ee1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833126000021/0001818331-26-000021-index.htm"},{"fact_type":"material_agreement","fact_key":"465e62de7b20bf8b913739283afd452a0701ab4a","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Existing Credit Agreement","agreement_type":"credit_facility","counterparty":"Perceptive Credit Holdings IV, LP","effective_date":"2026-02-27","item_codes_triggered":["1.02"],"value_text":"Repayment in full of existing term loan"},"claim":"GeneDx Holdings Corp. terminated Existing Credit Agreement with Perceptive Credit Holdings IV, LP valued at Repayment in full of existing term loan (effective 2026-02-27).","evidence_excerpt":"The proceeds of the Term Loan were used to repay in full the Company’s existing term loan under its existing Credit Agreement and Guaranty, dated as of October 27, 2023, by and among Sema4 OpCo, Inc. and GeneDx, LLC, as Borrowers, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP as the administrative agent and as a lender (the “Existing Credit Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818331-26-000021","anchor_url":"https://secwatch.observer/filing/0001818331-26-000021#claim-465e62de7b20bf8b913739283afd452a0701ab4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833126000021/0001818331-26-000021-index.htm"},{"fact_type":"material_agreement","fact_key":"94836d3efa850261f39e5a2371ef83165498037b","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Loan Agreement","agreement_type":"credit_facility","counterparty":"Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.","effective_date":"2026-02-27","item_codes_triggered":["1.01"],"value_text":"$100.0 million term loan"},"claim":"GeneDx Holdings Corp. entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. valued at $100.0 million term loan (effective 2026-02-27).","evidence_excerpt":"On February 27, 2026 (the “Closing Date”), GeneDx Holdings Corp. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”), with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries of the Company party thereto as Guarantors, Wilmington Trust, National Association, as Agent and the lenders from time to time party thereto (collectively, the “Lenders”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818331-26-000021","anchor_url":"https://secwatch.observer/filing/0001818331-26-000021#claim-94836d3efa850261f39e5a2371ef83165498037b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833126000021/0001818331-26-000021-index.htm"},{"fact_type":"executive_change","fact_key":"4cd1a04b2c","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2025-01-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-02","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Bryan Dechairo was appointed as Chief Operating Officer at GeneDx Holdings Corp..","evidence_excerpt":"On January 2, 2025, GeneDx Holdings Corp. (the “Company”) announced the appointment of Bryan Dechairo, Ph.D., age 52, in the newly created role of Chief Operating Officer, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001818331-25-000002","anchor_url":"https://secwatch.observer/filing/0001818331-25-000002#claim-4cd1a04b2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000002/0001818331-25-000002-index.htm"},{"fact_type":"material_agreement","fact_key":"ed9fa7b22c4fe7ebc6ca3340cf2df8365c319a97","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Sales Agreement","agreement_type":"atm_program","counterparty":"TD Securities (USA) LLC","effective_date":"2024-04-29","item_codes_triggered":["1.01"],"value_text":"up to $75.0 million"},"claim":"GeneDx Holdings Corp. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $75.0 million (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, GeneDx Holdings Corp. (the “Company”), entered into a sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC, as sales agent and/or principal (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time to or through TD Cowen, shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), having an aggregate offering price of up to $75.0 million (the “Shares”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818331-24-000031","anchor_url":"https://secwatch.observer/filing/0001818331-24-000031#claim-ed9fa7b22c4fe7ebc6ca3340cf2df8365c319a97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000031/0001818331-24-000031-index.htm"},{"fact_type":"earnings_release","fact_key":"4be3014127c6528e7905e9e224fb2b99da0bee2a","cik":1818331,"ticker":"WGS","company_name":"GeneDx Holdings Corp.","filed_at":"2024-04-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$8.5 million","period_text":"quarter ended March 31, 2024","report_date":"2024-04-29","result_type":"reported_results","revenue_text":"$61.5 million"},"claim":"GeneDx Holdings Corp. reported quarter ended March 31, 2024 results: revenue $61.5 million, net income $8.5 million. Guidance raised.","evidence_excerpt":"and reiterate our expectation to reach profitability in 2025.” First Quarter 2024 Financial Results (Unaudited) 1,2 Revenues • Revenues from continuing operations grew to $61.5 million, an increase of 51% year-over-year and 6% sequentially. ◦ Total company revenues were $62.4 million. • Exome and genome test revenue grew to $44.0 million, an increase of 96%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818331-24-000021","anchor_url":"https://secwatch.observer/filing/0001818331-24-000021#claim-4be3014127c6528e7905e9e224fb2b99da0bee2a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/0001818331-24-000021-index.htm"}]}